Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.
Key Publications in Pluripotent Stem Cell Research A Report from a Workshop of the International Stem Cell Banking Initiative, Held in Collaboration of Global Alliance for Ipsc Therapies and the Harvard Stem Cell Institute, Boston, 2017. (Stem Cells. 2019 Sep;37(9):1130-1135. doi: 10.1002/stem.3003. Epub 2019 Aug 6.) Autologous Induced Pluripotent Stem Cell-Derived Neurons to Treat Parkinson’s … Read more
Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.
Our lead clinical development program, ANPD001, is an autologous dopaminergic neuronal precursor cell (DANPC) therapy being studied in Parkinson’s disease (PD). (ANPD001) has received IND clearance and Fast Track designation from the U.S. Food and Drug Administration (FDA), and is currently under investigation in the ASPIRO Phase 1/2a trial for the treatment of Parkinson’s disease. … Read more
Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.
Aspen Neuroscience leverages stem cell biology and advanced genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.
Contact10835 Road to the Cure
Ste. 100
San Diego, CA 92121
© 2026 Aspen Neuroscience - All Rights Reserved